Keyword: AbbVie

Digital drug ads are gaining on TV in patient awareness and influence, according to a newly released patient study.

Express Scripts' change of strategy on specialty drugs could hit the top lines of Gilead, Sanofi and more, analysts fear.

AbbVie’s Humira, along with Pfizer’s Lyrica and Xeljanz, each spent more than $25 million on TV advertising for July.

It’s that time of year again—the time when lead PBM Express Scripts ignites pharma’s ire with a brand-new list of formulary exclusions.

At Orilissa's current price, only a quarter of eligible patients could get the drug without crossing the healthcare burden threshold, ICER estimates.

AbbVie has filed for a whopping 247 patent on Humira, an example of how drugmakers try to forestall copycat competition.

AbbVie is hitting the road this month to spur veterans toward hepatitis C testing in a cross-country bus tour with the American Legion.

A former Biogen sales manager has sued the company claiming she was let go after she filed a corporate integrity complaint.

AbbVie is bracing for European biosimilar competition to Humira, but the drug is still continuing its upward trajectory.

One of AbbVie’s most anticipated pipeline candidates—and a potential blockbuster aid after Humira biosims hit—has reached the regulatory finish line.